The effect of ramipril on ambulatory blood pressure: a multicenter trial.
The antihypertensive efficacy of ramipril was evaluated using 24-h noninvasive ambulatory sphygmomanometry in this double-blind, placebo-controlled study. One hundred subjects with mild-to-moderate essential hypertension were randomized to ramipril, 10 mg or placebo once daily for a 4-week treatment period. Ramipril decreased systolic and diastolic blood pressures throughout the 24-h period after dosing. Blood pressures measured manually 24 h postdose also showed that ramipril significantly reduced supine and standing blood pressures when compared with placebo. Incidences of adverse events were similar in the two study groups. Ramipril proved to be a well-tolerated agent with a sustained 24-h antihypertensive effect in this study.
Burris
J F
JF
Cardiovascular Center of Northern Virginia, Alexandria.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D015924:Blood Pressure Monitors; D001643:Bridged Bicyclo Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D017257:Ramipril
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001643:Bridged Bicyclo Compounds; D017257:Ramipril